Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2013

View Archived Issues

Novel candidate JNK1 inhibitors patented

U.S. group prepares new HCV treatments

Novo Nordisk releases financial statement for 2012

Dainippon Sumitomo Pharma updates activities of third quarter of fiscal 2012

Huntington's disease model extensively characterized

Study results inform phase III trial design for enterovirus 71 vaccine

Novel inhibitors of Janus kinases developed at Roche

Enkephalin analgesics divulged by Pfizer

Phenex Pharmaceuticals reported new FXR modulators

Gilead Sciences reports topline results from phase III sofosbuvir studies

Kymab launches program to develop monoclonal antibody therapeutics

StemEx product shows efficacy in phase II/III hematological malignancy study

First patient receives treatment in phase IIa NurOwn stem cell therapy trial

Pooled data study finds cardiovascular safety similar between peginesatide and comparators

Japanese government provides funding for unoprostone isopropyl development

Glenmark Pharmaceuticals discovers novel monoclonal antibody targeting OX40

The Medicines Company and Alnylam to develop therapeutics for hypercholesterolemia

Rockwell Medical's PRIME study meets primary endpoint

Biotest launches Bivigam for primary humoral immunodeficiency

NAD kinase inhibition has oncolytic potential

European approval for Zaltrap in metastatic colorectal cancer

FDA issues complete response letter for Ampligen in chronic fatigue syndrome

Medigene expands clinical development plan for RhuDex

Preclinical findings show promise of hpSC-derived neuronal cells for Parkinson's disease

Idenix discontinues IDX-184 and IDX-19368 HCV programs